Nuwellis Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Nuwellis Inc trades at $2.84 (market cap $1.09M), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.35. Which is the better fit depends on your goals.
| NUWE | TMF | |
|---|---|---|
Market Cap | $1.09M | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $527.46 | $44.14 |
52-Week Low | $2.80 | $31.85 |
Enterprise Value | -$722.58K | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% on the day, reflecting a bearish technical trend with moving averages signaling sell pressure. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights its significant long-term decline, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields and Federal Reserve policy. While some analysts see potential at the lower end of the trading range, the fund's structure makes it unsuitable for long-term holding due to volatility decay. Key risks include rising interest rates, inflation expectations, and the inherent leverage mechanism that amplifies losses. It remains a high-risk, tactical instrument for short-term traders.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →